Fight Aging! Newsletter, September 19th 2022

Conclusion Use of the Khavinson peptides and melatonin in combination in this way, at this dose, negatively impacts the thymus, producing a reduction in active tissue and increase in atrophy to fatty tissue. The degree to which this atrophy occurred is greater than one would expect to take place over nine months of aging at this stage of life. Why did this outcome occur, given the animal studies showing thymic regrowth, and the studies showing reduced later life mortality following use of thymogen? We can only speculate. Firstly, the dose makes the poison, and the dosing here may have been too high, too frequent. In one of the human studies, testing thymogen only, dosing for ten days occurred only one every six months, rather than monthly as here. Secondly, it may be that these peptides are pleiotropic in their effect on the thymus, and only beneficial after the thymus is very atrophied. Thirdly, it may be that in humans any benefit to the use of Khavinson peptides arises from increased peripheral T cell replication in useful populations, such as naive T cells. This could be beneficial on balance in late life, allowing greater resistance to infection, even if it pushes the patient further towards the accumulation of senescent and exhausted T cells. Lastly, the existing study data for Khavinson peptides relevant to this exercise may simply be dubious, wrong, or otherwise bad. On Reverse Cholesterol Transport Solutions to Atherosclerosis https://www.fig...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs